QIAGEN Makes Proposal to Fully Acquire Ipsogen

Featured In: Supplier News

Wednesday, June 15, 2024

See today's top life science stories and headlines - Sign up now!

newsvine diigo google
slashdot
Share
Loading...

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological (blood) cancers. The acquisition of Ipsogen, a publicly listed company founded in 1999 and based in Marseilles, France, would provide QIAGEN access to a broad range of assays covering 15 biomarkers used worldwide for the diagnosis, prognosis and monitoring of patients with various blood cancers. Many of these assays also are used as companion diagnostics in personalized healthcare to make and guide treatment decisions.

Almost all of Ipsogen’s assays have CE-IVD Marking in Europe and can be used on QIAGEN’s Rotor-Gene Q real-time PCR system, which will enable the smooth and rapid transfer of these unique products onto QIAGEN’s QIAsymphony RGQ, a novel integrated sample-to-result laboratory automation platform that includes the Rotor-Gene Q system.

“The acquisition of Ipsogen would further expand our global leadership in molecular assays for profiling and personalized healthcare,” said Peer Schatz, Chief Executive Officer of QIAGEN N.V. “Ipsogen’s molecular cancer profiling and personalized healthcare assays are clearly setting standards for the diagnosis and monitoring of many types of blood cancers as well as the selection and guidance of therapies. This portfolio would further increase our leading position in profiling assays, as well as in companion diagnostics for personalized healthcare, helping to improve the treatment of many diseases and addressing unmet medical needs.”

QIAGEN’s leadership in companion diagnostics for personalized healthcare is driven by more than 20 molecular diagnostic assays available in select regions of the world as well as more than 15 projects under way with pharmaceutical companies.

Ipsogen, which has approximately 70 employees at sites in France and the United States, reported 24% net sales growth in 2010 to €8.4 million (approximately $11 million) from a group of more than 400 active customers around the world. More than 40% of net sales were reinvested during 2010 into R&D activities.

All three managing cofounders – Vincent Fert (Chief Executive Officer), Stéphane Debono (Chief Operating Officer) and Fabienne Hermitte (R&D and Regulatory Affairs Senior Director) – are expected to stay with QIAGEN following the acquisition and contribute to the combined future mission.

“Ipsogen has created a portfolio of molecular assays that are advancing treatment standards for patients with blood cancers, and we are now moving forward in creating new products to support women with breast cancer,” said Vincent Fert, Chief Executive Officer of Ipsogen S.A. “As part of QIAGEN, we believe our efforts would be accelerated and benefit from an industry-leading company and could offer even greater options to patients and healthcare providers around the world.”

Ipsogen provides significant expertise in molecular diagnostics for blood cancers
Ipsogen is a pioneer in developing and marketing a range of cancer profiling and personalized healthcare diagnostics that help map diseases and guide the decisions of physicians and patients in the area of blood cancers. These advanced diagnostics provide significant benefits, particularly to patients by improving standards of care as well as to healthcare payors by optimizing overall treatment costs. These tests also provide advantages to physicians by enabling them to personalize therapeutic strategies, while pharmaceutical companies can optimize development of new medicines to target patients most likely to benefit.

Ipsogen’s tests are based on the same PCR quantitative technology (polymerase chain reaction) used by QIAGEN in many of its own assays. PCR technology allows for the detection and measurement of molecular abnormalities in cancerous cells in a very precise and highly sensitive way.

The approximately 80 tests offered by Ipsogen are divided into four assay families, with products designed for specific needs in terms of diagnosis, prognosis and monitoring:

  • BCR-ABL (Chronic Myeloid Leukemia)
  • JAK2 V617F (various myeloproliferative diseases)
  • PML-RARA (Promyelocytic Leukemia)
  • A group of several products for use with a range of rare forms of leukemia

Ipsogen’s tests are currently being used as a qualitative assay to diagnose various myeloproliferative diseases, a group of conditions that cause blood cells to grow abnormally in the bone marrow. These tests also are increasingly used as a quantitative technology in monitoring therapy.

The top-selling group involves molecular assays for the diagnosis and monitoring of mutations of the JAK2 (Janus kinase 2) gene, which is associated with various blood cancers and is targeted by many biotechnology compounds in pharmaceutical R&D. Ipsogen has a competitive advantage based on its exclusive worldwide license for a key mutation of the JAK2 gene, which it obtained in 2006. It has been strengthening intellectual property protection for this key biomarker while building up a group of more than 20 licensed partners around the world. In 2010, for example, the U.S. Patent and Trademark Office granted additional intellectual property claims to Ipsogen for detecting and using the JAK2 V617F mutation for diagnostic purposes.

Ipsogen also is developing the Genomic Grade test (GG), a multigene expression test that seeks to address unmet diagnostic needs for women with early invasive hormone-receptor positive breast cancer.

Upon completion of the offer, Ipsogen’s Marseilles site is planned to become a global center of excellence within QIAGEN focused on leukemia and breast cancer, and will also become a center for the development and manufacturing of other molecular tests.

Transaction summary
QIAGEN and a group of Ipsogen shareholders have entered into exclusive negotiations for QIAGEN to purchase approximately 47% of Ipsogen’s outstanding shares currently held or controlled by company cofounders and members of the Board of Directors on the basis of QIAGEN’s offer at €12.90 per share.

In addition, after the signing of the definitive purchase agreement and consummation of the purchase, QIAGEN would launch a process to acquire all remaining shares for €12.90 per share. This offer would represent a 71.3% premium to Ipsogen’s share price of €7.53 on June 13, 2011, the last trading day before this announcement. The total value to fully acquire Ipsogen is valued at approximately €70 million (fully diluted). Based on a currency exchange rate of €1.00 = $1.44 (market rate as of June 14, 2024), the transaction is valued at approximately $101 million (or approximately six times Ipsogen’s anticipated full-year 2012 net sales based on current estimates).

The Ipsogen Board of Directors has favorably welcomed this offer, and the Board members are among the shareholders who have agreed to this exclusivity. The workers’ council of Ipsogen is being consulted on the QIAGEN offer for its opinion.

QIAGEN would fund this acquisition from existing cash. The purchase and subsequent public offer are expected to be completed by the end of the third quarter of 2011. On an adjusted basis, which excludes one-time charges and integration costs, and amortization of acquisition-related intangible assets, the transaction would be expected to be slightly dilutive to adjusted EPS in 2012, but accretive to adjusted EPS beginning in 2013.

Rothschild and Kempen & Co. are acting as financial advisors and Darrois Villey Maillot Brochier is acting as legal advisor to QIAGEN in relation to this offer.

Source: QIAGEN N.V.

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Bringing the Cell Image into Focus

Nov 2 2010

Improvements in transmission electron microscope (TEM) technology increase the power of this imaging tool for the study of cell biology.

Finding a Cure for Spinal Cord Injury with On-Demand LIMS

Oct 25 2010

The Miami Project to Cure Paralysis finds an on-demand laboratory information management system (LIMS) helps to accelerate discovery in its HCS projects.

Saving Cells: Image Processing for Improved Viability, Part II: Iterative Deconvolution

Oct 25 2010

3D light microscopy and deconvolution provide a means to investigate 3D structure, providing near-confocal quality images without the temporal requirements or potentially damaging phototoxicity associated with other 3D imaging technologies. This article is Part II in a series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part I focused on spectral unmixing.

Saving Cells: Image Processing for Improved Viability

Sep 22 2010

This article is Part I of a two-part series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part II will focus on deconvolution.

Evaluation of a New Nano-Type UV-Vis Spectrophotometer

Mar 3

Analysis of one- to four-microliter size samples for nucleic acids has become routine in many life science laboratories. However, until now, available instruments require considerable manipulation of the instrument and sample; some require manually recording the data. The user must typically lower and raise the arm manually, then wipe the sample manually from the target after each analysis. And fiberoptics used in some of these instruments are subject to deterioration.

Production of Recombinant Proteins and Monoclonal Antibodies in Hollow Fiber Bioreactors

Jan 25

While well-understood, robust and convenient, classical batch-style 2-D culture on non-porous supports or 3-D suspension culture in other devices are really not very biologically relevant models. Cell culture conditions can affect the quality of the antibody or protein produced.

Selecting Robots for Use in Drug Discovery and Testing

Dec 6 2010

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Sep 13 2010

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11 2010

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2 2010

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1 2010

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Displacement above the hypocenter of the 2011 Tohoku-Oki earthquake.

37 minutes ago

The moment magnitude (M(w)) = 9.0 2011 Tohoku-Oki mega-thrust earthquake occurred off the coast of northeastern Japan. Combining Global Positioning System (GPS) and acoustic data, we detected very large sea-floor movements associated with this event directly...

From glutamate co-release to vesicular synergy: vesicular glutamate transporters

14 hours ago

On page 209 of the above article, 'Nucleus accumbensb33-35, neostriatum33-35' should be listed under 'Terminals' not 'Cell bodies'. The online version of the article has been corrected accordingly.

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   
Loading...

Free Life Science Industry
Subscriptions

Magazine

wireless week

Newsletters

newsletters

Sign up now



MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11 2010

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter

Information: